Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;8(9):e1001095.
doi: 10.1371/journal.pmed.1001095. Epub 2011 Sep 20.

Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti

Serena P Koenig  1 , Heejung Bang, Patrice Severe, Marc Antoine Jean Juste, Alex Ambroise, Alison Edwards, Jessica Hippolyte, Daniel W Fitzgerald, Jolion McGreevy, Cynthia Riviere, Serge Marcelin, Rode Secours, Warren D Johnson, Jean W Pape, Bruce R Schackman
Affiliations
Randomized Controlled Trial

Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti

Serena P Koenig et al. PLoS Med. 2011 Sep.

Abstract

Background: In a randomized clinical trial of early versus standard antiretroviral therapy (ART) in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm³ in Haiti, early ART decreased mortality by 75%. We assessed the cost-effectiveness of early versus standard ART in this trial.

Methods and findings: Trial data included use of ART and other medications, laboratory tests, outpatient visits, radiographic studies, procedures, and hospital services. Medication, laboratory, radiograph, labor, and overhead costs were from the study clinic, and hospital and procedure costs were from local providers. We evaluated cost per year of life saved (YLS), including patient and caregiver costs, with a median of 21 months and maximum of 36 months of follow-up, and with costs and life expectancy discounted at 3% per annum. Between 2005 and 2008, 816 participants were enrolled and followed for a median of 21 months. Mean total costs per patient during the trial were US$1,381 for early ART and US$1,033 for standard ART. After excluding research-related laboratory tests without clinical benefit, costs were US$1,158 (early ART) and US$979 (standard ART). Early ART patients had higher mean costs for ART (US$398 versus US$81) but lower costs for non-ART medications, CD4 cell counts, clinically indicated tests, and radiographs (US$275 versus US$384). The cost-effectiveness ratio after a maximum of 3 years for early versus standard ART was US$3,975/YLS (95% CI US$2,129/YLS-US$9,979/YLS) including research-related tests, and US$2,050/YLS excluding research-related tests (95% CI US$722/YLS-US$5,537/YLS).

Conclusions: Initiating ART in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm³ in Haiti, consistent with World Health Organization advice, was cost-effective (US$/YLS <3 times gross domestic product per capita) after a maximum of 3 years, after excluding research-related laboratory tests.

Trial registration: ClinicalTrials.gov NCT00120510.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Cost-effectiveness acceptability curves for earlier initiation of ART after a maximum of 3 y including and excluding protocol-driven costs.
Curves were constructed from 100 bootstrap simulations including protocol-driven costs and 100 bootstrap simulations excluding protocol-driven costs.
See this image and copyright information in PMC

References

    1. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. Available: http://www.who.int/hiv/pub/arv/advice/en/index.html. Accessed 14 May 2010. - PubMed
    1. Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265. - PMC - PubMed
    1. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–1144. - PubMed
    1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector - progress report 2010. 2010. Available: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 4 March 2011.
    1. Republique d'Haiti Programme National de Lutte contre le Sida. Rapport de situation nationale à l' intention de l'UNGASS. 2010. Available: http://data.unaids.org/pub/Report/2010/haiti_2010_country_progress_repor.... Accessed 14 May 2010.

Publication types

Substances

Associated data